{"id":768635,"date":"2023-07-10T13:35:27","date_gmt":"2023-07-10T17:35:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/"},"modified":"2023-07-10T13:35:27","modified_gmt":"2023-07-10T17:35:27","slug":"investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/","title":{"rendered":"Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ATLANTA, July  10, 2023  (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether BioXcel Therapeutics, Inc. (\u201cBioXcel,\u201d\u202for the \u201cCompany\u201d) (NASDAQ: BTAI) complied with federal securities laws.\u00a0 On June 29, 2023, the Company disclosed that it is conducting an investigation relating to its TRANQUILITY II Phase 3 clinical trial, specifically in regard to \u201cprotocol adherence and data integrity at the principal investigator\u2019s trial site.\u201d Following this news, the price of the Company\u2019s stock dropped.\u00a0<\/p>\n<p align=\"justify\">If you purchased BioXcel Fusion stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=75_6wNowMFuH6zPPqoT1MlFWmo8gsvbCJeTXGVpEY6ok8Z6Pa9RnGH5-WIPdKV4LczO4BnD8GTGHUGiJGE9IYUI3bRnkKX3BTivg2JZivYA=\" rel=\"nofollow noopener\" target=\"_blank\">cholzer@holzerlaw.com<\/a> or Joshua Karr, Esq. at\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pAbAipQS8XUEG1Vjo-TPDZywfzwgVXBzLl3DXTj-oQLHVN-Ym91tI_bc-qvkaQC98T8AhuIHkgADBOfIniX4K6oMsNxvT3iCb0IfRm-F2N4=\" rel=\"nofollow noopener\" target=\"_blank\"><u>jkarr@holzerlaw.com<\/u><\/a>, call our toll-free number at (888) 508-6832, or visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5BMRgDRJWyYrxBf9Zvh8jeyJUjRDN14XqmiOJwjIhRDDneBtrjWB5JxKfK5qHkRZ77TFGwJj97MGj1r_Brrq_BO60h27CPiiymvwymn3xOtt9sBniMa6SCME6tV4Ynxw\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.holzerlaw.com\/case\/bioxcel\/<\/u><\/a> to discuss your legal rights.<\/p>\n<p align=\"justify\">Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer &amp; Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.\u202fMore information about the firm is available through its website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5BMRgDRJWyYrxBf9Zvh8jbknJ3fakiWwwjcM4Uikh0tuZ-cilwBWO26TOLjT8en3xsHiwQHkjAeMdHIT_8EYJA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.holzerlaw.com<\/u><\/a>,\u202fand upon request from the firm. Holzer &amp; Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.\u202f\u00a0<br \/>\u202f\u00a0<br \/>CONTACT:\u202f\u00a0<br \/>Corey Holzer, Esq.<br \/>(888) 508-6832 (toll-free) <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=75_6wNowMFuH6zPPqoT1MlFWmo8gsvbCJeTXGVpEY6qCzHtczMyeUi9oFCg1eXwiLZxGcuLRSBCTLZIUNw37j4AvzeJKFWe83mxTzL4MCSM=\" rel=\"nofollow noopener\" target=\"_blank\">cholzer@holzerlaw.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTY3NiM1Njg0NDU2IzIxODA3Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NTA2N2ZkNGYtNjNiMC00NTYwLWJlZGMtZjllNDMyODA1Njk3LTExOTIzMzY=\/tiny\/Holzer-Holzer.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, July 10, 2023 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether BioXcel Therapeutics, Inc. (\u201cBioXcel,\u201d\u202for the \u201cCompany\u201d) (NASDAQ: BTAI) complied with federal securities laws.\u00a0 On June 29, 2023, the Company disclosed that it is conducting an investigation relating to its TRANQUILITY II Phase 3 clinical trial, specifically in regard to \u201cprotocol adherence and data integrity at the principal investigator\u2019s trial site.\u201d Following this news, the price of the Company\u2019s stock dropped.\u00a0 If you purchased BioXcel Fusion stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. cholzer@holzerlaw.com or Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com\/case\/bioxcel\/ to discuss your legal rights. Holzer &amp; Holzer, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-768635","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, July 10, 2023 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether BioXcel Therapeutics, Inc. (\u201cBioXcel,\u201d\u202for the \u201cCompany\u201d) (NASDAQ: BTAI) complied with federal securities laws.\u00a0 On June 29, 2023, the Company disclosed that it is conducting an investigation relating to its TRANQUILITY II Phase 3 clinical trial, specifically in regard to \u201cprotocol adherence and data integrity at the principal investigator\u2019s trial site.\u201d Following this news, the price of the Company\u2019s stock dropped.\u00a0 If you purchased BioXcel Fusion stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. cholzer@holzerlaw.com or Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com\/case\/bioxcel\/ to discuss your legal rights. Holzer &amp; Holzer, &hellip; Continue reading &quot;Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-10T17:35:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTY3NiM1Njg0NDU2IzIxODA3Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC\",\"datePublished\":\"2023-07-10T17:35:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\\\/\"},\"wordCount\":250,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTY3NiM1Njg0NDU2IzIxODA3Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\\\/\",\"name\":\"Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTY3NiM1Njg0NDU2IzIxODA3Njc=\",\"datePublished\":\"2023-07-10T17:35:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTY3NiM1Njg0NDU2IzIxODA3Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTY3NiM1Njg0NDU2IzIxODA3Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/","og_locale":"en_US","og_type":"article","og_title":"Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk","og_description":"ATLANTA, July 10, 2023 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether BioXcel Therapeutics, Inc. (\u201cBioXcel,\u201d\u202for the \u201cCompany\u201d) (NASDAQ: BTAI) complied with federal securities laws.\u00a0 On June 29, 2023, the Company disclosed that it is conducting an investigation relating to its TRANQUILITY II Phase 3 clinical trial, specifically in regard to \u201cprotocol adherence and data integrity at the principal investigator\u2019s trial site.\u201d Following this news, the price of the Company\u2019s stock dropped.\u00a0 If you purchased BioXcel Fusion stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. cholzer@holzerlaw.com or Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com\/case\/bioxcel\/ to discuss your legal rights. Holzer &amp; Holzer, &hellip; Continue reading \"Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-10T17:35:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTY3NiM1Njg0NDU2IzIxODA3Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC","datePublished":"2023-07-10T17:35:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/"},"wordCount":250,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTY3NiM1Njg0NDU2IzIxODA3Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/","name":"Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTY3NiM1Njg0NDU2IzIxODA3Njc=","datePublished":"2023-07-10T17:35:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTY3NiM1Njg0NDU2IzIxODA3Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTY3NiM1Njg0NDU2IzIxODA3Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-bioxcel-therapeutics-inc-btai-announced-by-holzer-holzer-llc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investigation of BioXcel Therapeutics, Inc. (BTAI) Announced by Holzer &amp; Holzer, LLC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=768635"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768635\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=768635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=768635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=768635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}